ST Pharm Co Ltd
KOSDAQ:237690
ST Pharm Co Ltd
Net Income (Common)
ST Pharm Co Ltd
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Net Income (Common)
₩22B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Samsung Biologics Co Ltd
KRX:207940
|
Net Income (Common)
₩895.3B
|
CAGR 3-Years
50%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
P
|
Peptron Inc
KOSDAQ:087010
|
Net Income (Common)
-₩15.9B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Net Income (Common)
-₩7.6B
|
CAGR 3-Years
23%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Net Income (Common)
-₩73.7B
|
CAGR 3-Years
-119%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-29%
|
C
|
Cellivery Therapeutics Inc
KOSDAQ:268600
|
Net Income (Common)
-₩75.2B
|
CAGR 3-Years
-56%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
See Also
What is ST Pharm Co Ltd's Net Income (Common)?
Net Income (Common)
22B
KRW
Based on the financial report for Mar 31, 2024, ST Pharm Co Ltd's Net Income (Common) amounts to 22B KRW.
What is ST Pharm Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 1Y
11%
Over the last year, the Net Income (Common) growth was 11%.